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Abstract 
Differential diagnosis of the etiology of visual hallucinations is challenging. Although visual 
hallucinations can be symptomatic of psychiatric disorder, they more commonly indicate 
neurological or medical disorders, sensory impairment, or substance intoxication or withdrawal.  
Accurate diagnosis and treatment is crucial given that misdiagnosis and incorrect treatment 
intervention can have profound consequences. The purpose of this paper is to summarize the 
most prevalent causes of visual hallucinations, review the DSM-5 hallucination decision tree, 
and provide an annotated visual hallucination differential diagnosis decision tree.  
Keywords: Visual hallucination, differential diagnosis, decision tree 
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Visual Hallucinations Differential Diagnosis Decision Tree 
While I was training as a psychology graduate student on a neuropsychology practicum, a 
patient presented for a neuropsychological evaluation with a personal history of visual 
hallucinations. The referral question was to assess his current level of cognitive functioning and 
to make a differential diagnosis. Rule outs included major depression with psychotic features and 
dementia with Lewy bodies. If he had depression with psychotic features, psychiatry would 
likely begin a trial of antipsychotic medication in addition to his antidepressant medication. If it 
was determined to be dementia with Lewy bodies certain antipsychotics may be contraindicated.  
Ultimately, it was determined that the patient had serotonergic syndrome after mixing 
antidepressant medications with over-the-counter herbal supplements.  He had initially denied 
taking supplements, but subsequently acknowledged doing so after neuropsychological testing.  
Visual hallucinations can be indicative of a wide range of disorders, both psychiatric and 
non-psychiatric in nature.  Visual hallucinations are one potential feature of psychosis, and a 
psychology trainee should be well versed in the various non-affective and affective psychiatric 
disorders that most commonly give rise to them, such as schizophrenia, bi-polar disorder, and 
depression. However, a wide range of neurologic and medical conditions can present with visual 
hallucinations, including seizures, metabolic or endocrine disorders, and infection, and these may 
require immediate medical attention and specialized medical knowledge to adequately diagnose.  
Visual hallucinations may also be related to substance intoxication or withdrawal, which may or 
may not be comorbid with underlying psychiatric and/or non-psychiatric conditions. Visual 
hallucinations may also be related to sleep disturbances. They may also fall into the realm of 
normal experience, particularly if occurring immediately before or after sleep, or following the 
death of a loved one (Teeple, Caplan, & Stern, 2009).  
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Examining the potential etiologies of visual hallucinations regarding the case above made 
me wish for a systematic visual hallucination differential diagnostic decision tree. This desire 
prompted the idea for this paper; to present a beginning framework and questions to guide a 
psychology trainee through the steps of what to consider at each decision tree juncture.  This 
experience also prompted me to examine the process, potential for misdiagnosis, and logical 
errors that may occur with differential diagnosis.   
Diagnosis itself has many potential functions. Diagnosis should be valid and more 
importantly useful (Kendall & Jablensky, 2003). Diagnosis has the greatest utility when it 
informs evidence-based treatment options, identified in a timely manner (McGorry & van Os, 
2013). Diagnosis may be used to label or to identify a condition or set of symptoms, provide 
shorthand for clinicians to communicate with each other, and help with billing codification and 
payment. Accurate diagnosis may help to promote understanding of the disorder and the 
potential course of the disorder. Diagnosis may impact a patient's access to care. Diagnosis may 
also be used to stigmatize.  
Diagnoses from the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition, 2013), and to a lesser extent the ICD-10 (International Statistical Classification of 
Diseases and Related Health Problems, Tenth Edition, 1990), often are used in a top down 
approach.  A clinician starts with the suspected diagnosis or diagnoses and then compares the 
presentation, and if possible the course of the presentation and response to treatment. The top 
down approach although often used, is not recommended because it is subject to confirmation 
bias and assumes reliability within categories, which is often not the case.  
Starting with a symptom, such as visual hallucinations, leads to a bottom to top approach 
to diagnosis. In theory one would consider all of the possible etiologies of the symptom and 
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work upwards towards differential diagnosis in a systematic manner attempting to recognize the 
pattern of the symptom as it relates to potential diagnoses. The bottom-to-top approach would 
not be useful if the symptom was common such as a headache, fever, or low mood. However, 
with a symptom that is rare this approach is useful.   
Beside this limitation, the bottom-to-top approach has several benefits and drawbacks. 
This approach creates the potential for improved diagnostic accuracy. In addition, increased 
awareness and understanding of the mechanisms underlying varying diagnoses with similar 
symptomology, could potentially inform future research and treatment. Downsides include the 
amount of additional time and expense it could take to make a diagnosis, which in many cases 
may not be an available luxury. Another downside is the knowledge base required to approach a 
diagnosis in this manner. Expecting a single clinician to have a substantial fund of knowledge of 
all the potential diagnoses related to visual hallucination that occur across various fields and 
disciplines is unrealistic.  
Thus, creating a single decision tree is challenging. Given that visual hallucinations can 
initially present to providers in many medical and mental health disciplines, including 
psychiatry, psychology, neurology, neuropsychology, emergency medical services, primary care, 
nursing, and assisted living, the interplay of these fields should be considered when making a 
diagnosis. These field specialties each have their own approaches to problem solving and 
different lenses through which to view differential diagnosis.  Doctors may refer to psychiatry, 
neuropsychology or psychology when the patient’s presentation does not fit the expected clinical 
picture, just as neuropsychology and psychology may refer a patient to neurology if the clinical 
picture is unclear and does not fit the expected pattern of presentation for a psychiatric disorder. 
Respect for the bounds, capabilities, limitations, ethical considerations, and awareness of the 
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assumptions of each field is warranted. However, a basic understanding of alternative 
explanations for visual hallucination and the prevalence rates of those disorders may help to lead 
to more accurate differential diagnosis and treatment. Therefore, information regarding the most 
prevalent etiologies of visual hallucinations, and prevalence rates in the general population as 
well as base rates in other more specific populations will be indicated when available.  
The hallucination decision tree of the DSM-5 Handbook of Differential Diagnosis (see 
Figure 1.0) (First, 2014) is used as an initial decision tree framework as applied to visual 
hallucinations. In this paper I will address the value and utility of the model, as well as the 
potential errors in clinical judgment, assessment, treatment, diagnosis, and logic this model may 
inadvertently perpetuate when applied to visual hallucinations. Questions regarding what to 
consider at each juncture of the decision tree will also be presented.  
Prevalence Rates and Differential Diagnosis 
It is important to remember the medical school saying attributed to Dr. Theodore 
Woodward, “When you hear hoof beats, think horses not zebras” (Sotos, 2006, p1). As clinicians, 
we increase our vulnerability to misdiagnosing if we do not sufficiently consider base rates and 
acknowledge the limits of our clinical judgment (Karson & Nadkarni, 2013).  In addition we are 
vulnerable to making rare diagnoses rather than seeing the more common diagnoses due to the 
availability heuristic; the phenomenon in which that which is more memorable stays in mind 
more than that which is more probable and because “the striking and novel stays longer in mind” 
(Sotos, 2006). We are also likely to look for a psychiatric condition rather than a medical 
condition with psychiatric features due to the availability of our training and fund of knowledge 
in psychology compared with the limited scope of our medical knowledge.  
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Prevalence rates do not conclusively tell if the individual patient has the diagnosis.  
Diagnosis depends on whether the individual patient has the disorder, not on a statistic based on 
the group (Harvey et.al, 1979).  However, given that there are usually alternate diagnoses to 
which the patient’s symptoms may fulfill diagnostic criteria, the clinician needs to remember that 
among those potential diagnoses, zebras and horses exist and may even be considered potential 
rule-outs, particularly if the presentation of the course of the disorder is not as expected.  
Prevalence rates may serve to remind the clinician what is statistically common in the group 
studied; they may indicate whether if one is looking at a zebra or a horse.  Put differently, in a 
Bayesian analysis, an oddity in presentation or history changes the situation and requires a 
different base rate.  Thus, the patient above not having taken supplements would have put him in 
a group where the base rate for the ultimate diagnosis was much lower than it was for the group 
that taking supplements put him in. If you are in Tanzania, think zebras not horses.  
Given the low prevalence/base rate of visual hallucinations, as well as the low base rates 
of the many etiologies behind them, caution is advised regarding base-rate fallacy. A discussion 
of base rates, Bayes theorem, base rate fallacy, and Sutton’s law is in order.  Regarding base 
rates, also called prevalence, it is important that the base rate/prevalence is the “naturally 
occurring rate of a condition in a population” (American Psychological Association, 2007, p. 
103).  Base-rate fallacy is a decision-making error in which information about rate of occurrence 
in a population (base rate information) is ignored or not given proper weight” (American 
Psychological Association, 2007, p. 103). For example, if I told you we were going to a business 
retreat island vacation and 90% of those on the island were psychologists and 10% were 
morticians, one might assume a gentleman on the island with an interest in dead bodies was one 
of the morticians and downplay the fact that 90% of the people are psychologists. “Bayes’ 
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theorem is a formula derived from probability theory that relates two conditional probabilities: 
the probability of the event A, given that even B has occurred, p(A/B), and the probability of 
event B given that event A has occurred, p(B/A). It serves as a basis for linking prior and 
antecedent probabilities” (American Psychological Association, 2007, p. 105).  The formula is as 
follows p(A│B)= p(B│A) p(A)/ p(B│A) p(A)  +  p(B│~A) p(~A). 
Suppose that a new blood test has been discovered that correctly identifies 90% of those 
with schizophrenia as having it, but falsely identifies those without schizophrenia as having it 
10% of the time. This sounds like a fairly good test, right? What do you intuitively assume the 
probability that a person actually has schizophrenia given a positive test result? For simplicity’s 
sake, assume that the prevalence rate of schizophrenia is 1% and A= an individual has 
schizophrenia and B= a positive test result. The equation would be  
(.90)(.01)/(.01)(.90)+(.99)(.10). The result would be an 8.3% chance of actually having 
schizophrenia with a positive test result (because the a priori probability is so low). Thus, 
intuitive judgment may get one into trouble with diagnosis. When the prevalence rate is so low 
and the diagnostic gold standard is not clear, there is incredible room for incorrect diagnosis.  
Clinicians also need to remember Sutton’s law, which states that a clinician should 
conduct assessment regarding the most obvious diagnosis first, balancing it against the potential 
of risk to the patient of not addressing another less common diagnosis (Rytand, 1980). In the 
differential diagnosis of the etiology of visual hallucinations, one needs to remember there are 
many zebras and a few horses, with the added concern that several of the diagnoses are 
potentially fatal.    
Regarding visual hallucinations, suppose the case of a 23 year old patient presenting at 2 
o’clock in the morning at an ER in New Orleans during Mardi Gras; statistically the visual 
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hallucinations are likely substance related, but not necessarily. Diagnosis could also be the onset 
of schizophrenia, a head injury, infection, or one of many other etiologies.  However, if the main 
presenting feature is visual hallucinations without auditory hallucinations the odds are again very 
low that it is schizophrenia in a non-inpatient environment, and presumably even lower in a non-
inpatient environment that is also a substance rich environment. For example, consider the 
prevalence rates for visual hallucinations of patients with schizophrenia are between 16-72%. 
The higher rates are gleaned from studies of patients in inpatient units, the lower rates are from 
studies of those with a diagnosis in the general population, and if visual hallucinations are 
present, auditory hallucinations are generally co-occurring, although not necessarily at the same 
time.  Given the prevalence of schizophrenia is estimated to be 0.7% according to the DSM-5 
that would mean the prevalence rate for an individual to present with a symptom of visual 
hallucinations is very low. In contrast between 7-25% of people presenting with psychotic 
features for the first time are determined to have substance/medication use or withdrawal in 
various populations. Also, considering the 23 year-old hallucinating at Mardi-Gras, it would be 
prudent to know first if the patient had used substances. Then one would rule-out the most likely 
life threatening causes by utilizing the simplest and most accurate measure, which has the lowest 
false positive rate. This spotlights another consideration: the base rate for diagnostic validity and 
specificity within a population.  
Regarding diagnostic validity and specificity, for the point of this discussion I am going 
to move from the Mardi-Gras example and consider Alzheimer’s disease. The gold standard of 
diagnostic accuracy for Alzheimer’s disease is diagnosis based on autopsy findings.  Not an ideal 
method of diagnostic accuracy when one hopes a patient to survive. This highlights the 
importance of balancing patient safety and diagnostic accuracy. However, prior to autopsy with 
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what specificity and sensitivity may diagnosis be made? The answer is so low as to recognize 
that it is generally diagnosed as probable Alzheimer’s disease.  
Considering, psychological diagnoses with what specificity and validity is a diagnosis of 
schizophrenia made? What is the gold standard of diagnosis?  What are the sensitivity and 
specificity of diagnostic measures? There have been multiple attempts to identify biological 
markers and early identifiers of schizophrenia and there is to date no gold standard of diagnosis 
(American Psychiatric Association, 2013). What are the base rates for false positives, false 
negatives, and diagnostic accuracy? As psychologists we diagnose based on what we believe we 
know and what we have learned as psychologists about symptom criteria that diagnoses describe, 
as well as what we know about the patient. We often take a history (psychiatric, social, and 
medical) of the patient and perhaps the patient’s family during a formal or informal interview, 
and if possible we may collect collateral information. From this information, clinicians attempt 
to determine what happened or changed prior to onset (e.g., was the onset acute or slow and 
insidious). Then we rule out likely alternate causes. Then clinicians compare the cluster of 
symptoms to the diagnostic cluster of symptoms accepted at the time as the diagnostic definition 
and determine whether what has been observed or reported fits the diagnosis. Clinicians may use 
psychological and neuropsychological assessment for diagnostic clarification as well. After 
diagnosis, if clinicians remain in contact with the patient, which may be a big if given many 
patient populations and clinical settings, clinicians the attempt to determine if the course of the 
disorder is as expected and responds to treatment as expected, or does not.  
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Neuropsychological/Psychological Assessment  
As stated above, as a part of differential diagnosis clinicians may use psychological 
assessment and/or neuropsychological assessment measures. The DSM-5 hallucination 
diagnostic decision tree lists neuropsychological performance as a factor to consider at several 
diagnostic junctures. Neurocognitive domains that may be assessed with neuropsychological 
assessment include complex attention, executive function, learning and memory, expressive and 
receptive language, perceptual motor abilities, and social cognition. Valuable data may be gained 
from testing to help inform the level of functioning and diagnosis, when compared to the 
patient’s history and current level of functioning. However, regarding neuropsychological 
assessment it is important to remember the diagnostic validity and specificity of the assessment 
measures used. 
Regarding the degree to which a measure tests what it is claiming to test (validity), the 
probability that a test accurately identifies those who do have the specific diagnosis (specificity) 
and the degree to which the test accurately identifies a negative diagnosis for those who do not 
have the diagnosis (American Psychological Association, 2007), it is important to remember the 
conclusion of the 1996 Neuropsychology Assessment panel: 
No neuropsychological tests have been shown to have consistent diagnostic validity. 
Some tests accurately distinguish between two or three diseases when samples of patients 
with these diseases are assessed, but no study has shown that neuropsychological tests 
have positive predictive values when a wide variety of disorders are tested” (593).  
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Neuropsychological tests provide data that can be used as part of the diagnostic process, 
but no neuropsychological test supersedes the judgment of the clinician.  Tests may be used to 
help quantify or describe a current level of function, but not to predict.  
In addition, researchers often mistake “the null hypothesis in research designs and group 
statistics (e.g. means, standard deviations, correlation coefficients, etc.) for research that directly 
quantifies how well (or how poorly) our tests actually quantify individuals” (Smith et al, p 40).   
This is said not to undercut the utility and value of neuropsychological testing in differential 
diagnosis, but to reiterate that group norms of expected performance of patients with a given 
disorder may be very similar to patterns of performance of groups of patients with other 
disorders as well, or even groups without identified disorders. Also, part of neuropsychological 
testing performance looks at deviation from the norm the individual has from the population, and 
what is expected given the patient’s age and education.  Individual testing performance can be 
influenced by anxiety, sleep deprivation, sickness, medication, pain, and many other variables. 
Even in “normals” being tested there is significant deviation from the norm by one standard 
deviation. As stated by Binder, Grant and Iverson:  
Abnormal performance on some proportion of neuropsychological tests in a battery is 
psychometrically normal. Abnormalities do not necessarily signify the presence of 
acquired brain dysfunction because low scores and large intra-individual variability often 
are characteristic of healthy adults. We recommend that test battery developers provide 
data on the amount of variability in normal samples and also provide base rate tables with 
false positive rates that can be used clinically when interpreting test performance (2009, 
p.31). 
For example the base rate for a 25-point score discrepancy on the Working Memory  
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Index for someone with an IQ score in the 90-109 range on the Wechsler Adult Intelligence 
Scale, Forth Edition (WAIS –IV )is 10.7%.  Another study addressing flexible 
neuropsychological batteries found “most (73%) of the healthy older adults had one or more 
scores at or below the 10th percentile and 37% had one or more scores at or below two standard 
deviations from the mean” (Binder, Iverson, & Brooks, 2009, p. 31; Palmer et al., 1998). Again, 
this is stated not to diminish the potential utility of testing, but to remind clinicians of what 
assessment can and cannot do. 
   Visual Hallucination 
At the first branch of the DSM-5 Hallucination Decision Tree one is to determine whether 
the symptom is a hallucination. Hallucination is defined in the DSM-5 as “a perception-like 
experience with clarity and impact but without the external stimulation of the relevant sensory 
organ” (American Psychiatric Association, 2013, p. 822). The DSM-5 further clarifies the 
definition by stating that visual hallucinations are to be distinguished from misperceptions or 
misinterpretations of an external event as occur in illusions. This definition does not sufficiently 
take into account attribution error, nor does it truly clarify what a visual hallucination is. 
Perception, imagination, and hallucination are identical in that they may all be classified as 
perception behaviors. They all involve the same behavior of seeing. However, in perception that 
which is seen is in front of you; in imagination it is not and you know it is not; in hallucination it 
is not but you think it is. The same behavior of seeing is happening whether the scene is there or 
not (Karson, 2006). Patients with insight regarding their hallucinations are often hesitant to tell 
providers of their hallucinatory experiences for fear of being seen as having a psychiatric 
condition (Shea, 1998).  Also, if a patient readily acknowledges that what was seen was not 
there, would this not be classified as a visual aberration instead of a visual hallucination? 
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Conversely, patients without insight are likely to not report hallucinations because they are 
unaware their experiences are hallucinatory. It is up to the provider to observe if a patient is 
acting as they are responding to a visual hallucination and to question about visual hallucinations 
in a manner that is open and reduces perceived stigma about hallucinations (Zuckerman, 2010; 
Shea, 1998). Providers must also consider whether there is potential gain to be obtained by the 
report and consider the possibility of malingering in such cases (Lezak, Howieson, Loring, 
Hannay, & Fischer, 2004).  
 Visual hallucinations with formed objects such as people are called complex 
hallucinations.  Those with unformed images such as auras, light flashes, or patterns are called 
simple hallucinations (Moore & Puri, 2012). Visual hallucinations that occur during the daytime 
and do not occur immediately before or after sleep have a lifetime prevalence rate of 3.2% in the 
general population (Ohayon, 2000). Hallucinations that occur while falling asleep (hypnogogic) 
or waking (hypnopompic) are considered “within the range of normal experience” (American 
Psychiatric Association, 2013, p. 88). Almost one-third of the general population may experience 
complex visual hallucinations while in the state proceeding or following sleep (Ohayon, 2000). 
However, although complex hallucinations affect normal populations, they also occur in 
pathological condition (Manford & Adermann, 1998). Visual hallucinations have a bimodal 
distribution prevalence with respect to age. Psychosis related visual hallucinations occur more 
often in late adolescence and early adulthood. Visual hallucination related to neurodegenerative 
disorders, and eye disease occur more frequently in elderly populations (Waters et al., 2014). 
Visual hallucinations may be a symptom of non-affective and affective psychiatric 
disorders, such as schizophrenia, bi-polar disorder, or depression (American Psychiatric 
Association, 2013).  Often patient report of visual hallucinations does generate psychiatric 
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consultation, even though visual hallucinations “are not pathognomonic of a primary psychiatric 
illness” (Teeple et al., 2009, p. 26). Although a feature of psychosis and often considered 
psychiatric in nature, the etiology of visual hallucinations is greatly varied, as are the appropriate 
treatments and interventions.  
Visual hallucinations are frequently indicators of a number of neurologic and medical 
conditions such as seizures, metabolic or endocrine disorders, and infection, as well as substance 
intoxication or withdrawal, rather than indicative of psychiatric disorder (Cummings & Miller, 
1987; Duwe & Turetsky, 2002; Hall, Popkin, Devaul, & Faillace, 1978; Sacks, 2013; Shea, 
1998; Teeple et al., 2009). Hallucinations due to neurological or medical disorders often are 
distinguishable from schizophrenia spectrum disorders by having a higher prevalence of 
prominent visual hallucinations, and a lower prevalence of bizarre behavior, thought disorder, 
rapid speech, and negative symptoms (Cornelius et al., 1991). However, the prevalence of visual 
hallucinations is higher than previously believed in psychiatric conditions (Waters et al., 2014).  
If and how visual hallucinations are etiologically related in psychosis, neurodegenerative 
disorders and eye disease remains unclear (Waters et al., 2014).  
There are multiple mimics of psychiatric dysfunction that should be considered when a 
patient initially presents with visual hallucinations (Teeple et al, 2009; Shea, 1998; Duwe & 
Turetsky, 2002). When a patient presents with a visual hallucination, one should suspect organic, 
medical or toxin etiologies (Shea, 1998). Disturbances in sleep are linked to visual 
hallucinations, even if a formal diagnosis of sleep disorder or narcolepsy is not present. Visual 
hallucinations linked to sleep disturbance are also found in Parkinson’s disease, PTSD, 
peduncular seizures, Lewy Body dementia, stoke, migraine, epilepsy, Charles Bonnet syndrome, 
and schizophrenia (Manford & Adermann, 1998).  
VISUAL HALLUCINATION DIFFERENTIAL DIAGNOSIS CHART  16 
Accurate diagnosis of the etiology of visual hallucinations can be difficult, especially 
given similar presentations between disorders, co-morbid conditions, and the low prevalence 
rates of many of the potential etiologies. Prompt medical evaluation is recommended with the 
initial presentation of psychotic features, particularly if onset is acute with no prior history of 
hallucination or other psychotic features (Hall, Popkin, Devaul, & Faillace, 1978; Shea, 1998). 
Proper diagnosis and treatment is crucial, as misdiagnosis of those with visual hallucinations can 
have profound and even life threatening consequences.  Even with careful psychiatric 
interviewing, medical examination and diagnosis, misdiagnosis does happen.  A clinician should 
be aware of treatment effectiveness and what does not fit the clinical and psychological picture 
and re-evaluate (Shea, 1998). For example, schizophrenia and narcolepsy can have similar 
symptom presentations and can be difficult to differentially diagnose (Talih, 2011). Studies have 
indicated that patients with narcolepsy have been misdiagnosed with schizophrenia, placed in 
psychiatric hospitals and treated with anti-psychotic drugs; in fact, antipsychotic drugs may 
increase the psychotic features, including visual hallucinations in patients with narcolepsy. An 
incorrect diagnosis can contribute to a cycle of psychiatric symptoms, hospitalization, decreased 
quality of life, and economic and societal impact continued in some cases for years until the 
correct diagnosis was identified and the incorrect treatment ceased. This is just one example of 
the potential profound impact of misdiagnosis.   
Given that neuropsychological testing, neurological imaging, lab tests and psychological 
testing all have their limitations regarding validity, specificity, and base rates of inaccurate 
diagnosis, and that norms for testing are based on the group norms, the psychiatric interview is 
an important diagnostic tool. The interview should obtain pertinent information regarding the 
patient’s age, substance/medication use and/or discontinuation, medical history, psychiatric 
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history, presence, onset, type of onset, behavioral, psychiatric, mood, or cognitive symptoms, 
estimated pre-morbid functioning, family medical, psychiatric and neurological histories. 
Attribution error and malingering should also be considered.   
Questions to be considered at this juncture are: 
1. Is the event described a hallucination, misperception, illusion, or imagination? 
2. Is there attribution error on the part of the patient or clinician? 
3. Is the hallucination hypnogogic or hypnopompic or not? 
4. What type of hallucination is it, complex or simple?   
5. Is insight intact? If so, how did the person identify the hallucination or visual 
aberration? 
6. Is the hallucination disturbing to the patient? 
7. What is the context of the hallucination? 
8. What was the duration of the hallucination? 
9. What does the patient believe the consequences of the hallucination are? 
10. Are other hallucinations or delusions present? 
11. Are there negative symptoms? 
12.  Is there potential gain or secondary gain? 
13. Is this the first time a visual hallucination has presented? If not, what were the 
previous hallucinations and in what context? 
Substance/Medication Induced Visual Hallucinations 
 The next juncture of the decision tree asks the clinician to determine whether the 
visual hallucination is due to the physiological effects of a substance/medication. Substance or 
medication use and/or withdrawal symptoms are statistically a likely cause of visual 
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hallucinations.  Substance use among patients presenting with first episode of psychosis is two 
times that of the general population (Barnett et al., 2007). Substance use is present in the 
majority of people presenting with first episode psychosis (Barnett et al., 2007), and “between 7-
25% of individuals presenting with a first episode of psychosis in different settings are reported 
to have substance/medication induced psychotic disorder,” with the higher rates reported in 
emergency room settings (American Psychiatric Association, 2013). However, it is possible that 
people with new onset psychotic disorders are more likely to use substances.  
Distinguishing between substance-related psychotic symptoms and primary psychotic 
illness is critical, because each requires different treatment. Some cases may require treatment 
with medication and medication may be contraindicated in other cases. Studies indicate that 
visual hallucinations were more common with substance related psychotic symptoms and that 
negative symptoms of psychosis were more frequently related with primary psychosis. However, 
studies also indicate, "psychotomimetic drug use may precipitate a chronic schizophrenic illness"  
(Caton et al., 2005, p. 143). According to the DSM-5 substance or medication induced psychotic 
disorder has unknown prevalence rates in the general population. Studies have indicated a 
prevalence rate of diagnosed substance induced psychotic disorder in the general population of 
0.43% (Perala et al., 2007). However, one should note that the statistic for those with diagnosed 
substance induced psychotic disorder does not include those with substance withdrawal, 
substance withdrawal delirium, substance intoxication, or substance intoxication delirium, all 
which may present with visual hallucinations. In my first year as a practicum student I noticed a 
patient in his 50’s looking around the room while I was speaking to him following surgery. 
When I asked him what he saw, he described seeing a mouse. There was no mouse, but he was 
unaware that he was beginning to have hallucinations related to alcohol withdrawal.  When 
VISUAL HALLUCINATION DIFFERENTIAL DIAGNOSIS CHART  19 
admitted to the hospital for surgery he had denied regular alcohol use. In fact he denied alcohol 
use until the unreality of the hallucination symptoms, the course of treatment and potential risks 
of alcohol withdrawal were described to him. Fortunately, when the patient was faced with 
potential medical complications his wife provided his heavy alcohol use history, and treatment 
with benzodiazepines ensued.  
Besides denial of substance use or withdrawal patients and/or providers may be unaware 
of or fail to research substance/medication interaction (Zuckerman, 2010), or the interaction may 
be unknown.  For example, suppose that you have a patient taking 16 prescribed medications, as 
well as herbal supplements and vitamins; it is likely that given all the permutations of substance 
interaction there are no available studies researching someone taking those 16 medications and 
additional supplements. The interactions and side effects may be unknown, particularly in an 
older patient who is medically compromised.  Patients may also not take their medication as 
prescribed.  Given these variables it is important for the clinician to keep substance/medication 
use or withdrawal in mind even after the initial consultation, particularly if the clinical picture 
remains unclear and psychological data does not fit the pattern of hallucinations and behavior.  
Symptoms of substance/medication intoxication and withdrawal include autonomic 
hyperactivity, pupillary dilation, nystagmus, sweating, increased hand tremor, insomnia, nausea, 
hallucinations, psychomotor agitation, anxiety, generalized tonic seizures, impaired judgment, 
and confusion. 
 Drugs and medications associated with visual hallucinations include street drugs such as 
alcohol, cocaine, PCP, methylenedioxymethamphetamine (Ecstasy), amphetamine, mescaline, d-
lysergic acid diethylamide (LSD), opioids, and cannabis; psychotropic medications such as 
benzodiazepines, L-dopa, dopaminergic, neuroleptic, anti-cholinergic, serotonergic, sedative, 
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anxiolytic, tricyclic antidepressants, benztropine, narcotics; non-psychotropic medications such 
as digoxin, glucocorticoids, amantadine, cimetidine, ranitidine, sildenafil, beta-blockers, 
clarithromycin; and over the counter drugs such as ephedrine and phenylpropanolamine (Liu, 
Volpe, & Galletta, 2001; APA, p. 482) . Substance/medication related visual hallucinations are 
one of the few horses in the diagnostic decision tree and combined with medical implications 
they should be a primary consideration and rule-out.    
Alcohol is the most commonly used drug associated with visual hallucinations. It is 
estimated that 12.4% of adult men and 4.9% of adult women have alcohol substance use 
disorder.  It is also estimated that approximately 50% of middle-class individuals with alcohol 
use disorder experience full alcohol withdrawal syndrome and more than 80% of those with 
alcohol use disorder who are hospitalized or homeless may experience withdrawal. Transient 
visual, auditory, and tactile hallucinations may accompany withdrawal. Hallucinations may occur 
outside of delirium. Less than 10% of those will develop alcohol withdrawal delirium or 
withdrawal seizures (American Psychiatric Association, 2013).  However, the answer to the 
question as to whether or not substance/medication use or withdrawal is involved can be more 
difficult to determine than one may initially anticipate. This determination is important because 
withdrawal from alcohol can be fatal for heavy drinkers, and if necessary, medical treatment 
should begin as soon as possible.  
Even before we have considered other substances such as stimulants, hallucinogens, 
opioids, sedatives, cannabis, and other medication, it is of note that it is statistically more likely 
for substance/medication involvement than psychiatric disorder alone. Also important 
statistically is the higher prevalence of substance use by young adults (American Psychiatric 
Association, 2013).  The prevalence rate of substance abuse among people with severe mental 
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illness is significantly higher than that in the general population.  Diagnostic accuracy is 
particularly critical in the onset of a psychiatric disorder, at a time when the clinical picture may 
be clouded by substance use (Caton et al., 2005). Diagnostic stability is also a question. Those 
diagnosed with drug-induced psychosis generally fall into one of two categories. Either the 
patients are discharged with no follow up for several years or they have a longer hospital stay, 
are referred to log-term follow-up care and have a change in diagnoses (Komuravelli, Poole, & 
Higgo, 2011). In addition to diagnostic accuracy, substance use history is also important because 
it is strongly correlated with non-compliance to psychiatric treatment (Weiss, Smith, Hull, 
Courtney, & Huppert, 2002).  
Regarding this juncture of the decision tree, it is important to consider:  
1. Which substances/medications have been used or discontinued? 
2. Are signs of autonomic disturbance, agitation, tremor, and other indicators of 
withdrawal apparent? 
3. Is medical referral necessary due to risk to patient?  
4. If substances are related, is there also a co-morbid psychiatric condition?  
5. You may not be getting the truth regarding substance use, continue to watch for 
signs of substance involvement, even if initially denied. 
6. Substance use/withdrawal related hallucinations often are visual, tactile and 
auditory and are usually transient, but may persist.  
7. Prevalence rate amongst the general population in various settings is 7-25%. 
8. The prevalence rate of substance use among young adults is higher, and 
prevalence rate of medication use among older adults is higher.  
VISUAL HALLUCINATION DIFFERENTIAL DIAGNOSIS CHART  22 
9. Substance use is much more frequent among those with primary psychiatric 
disorders than the general population. 
10. Medications such as antipsychotic and psychotomimetic medications may be 
contraindicated. 
 
Visual Hallucinations Due to Physiological Effects of Medical Condition 
The next juncture of the DSM-5 hallucination decision tree asks the clinician to 
determine if the hallucination is due the physiological effects of a medical condition and then to 
consider whether the patient presents with fluctuating attention and awareness, indicating 
delirium, or with neurocognitive impairment in at least one cognitive domain such as complex 
attention, executive function, social cognition, perceptual motor ability, language, learning and 
memory. The DSM-5 has reclassified Dementia, Delirium, Amnestic, and Other Cognitive 
Disorders as Neurocognitive Disorders (NCD). Visual hallucinations related to physiologic 
conditions may range from simple to complex and the patient may or may not have insight that 
the hallucination is a hallucination and not real.  As with determining whether a hallucination is 
substance or medication related, determining if a hallucination is due to a medical condition is 
crucial as some of the conditions associated with visual hallucinations are life threatening and 
prompt treatment is imperative (Shea, 1998; Teeple et al., 2009).  
Delirium 
The clinician is first asked to determine whether the patient is experiencing delirium. 
Delirium is a medical condition and can indicate life threatening medical disorders. Delirium is 
defined as a “disturbance of attention or awareness that is accompanied by a change in baseline 
cognition that cannot be better explained by existing or evolving neurocognitive disorder” 
(American Psychiatric Association, 2013, p. 599).  The change develops over a short period of 
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time from a few hours to a few days and may fluctuate over the course of a day (American 
Psychiatric Association, 2013).  However, delirium is not always acute in onset and it is possible 
for onset to be insidious (Shea, 1998).  
In the general population the prevalence of delirium is 1-2%, but it is as high as 14% in 
those over 85 years of age. The prevalence of delirium in patients at hospital admission ranges 
from 14%-24%. Prevalence rates for delirium during hospitalization range from 6%-56% in 
general hospital settings and 70%- 87% of older individuals in intensive care. Prevalence rates 
for delirium at the end of life are as high as 83% for all individuals.  
Delirium may precede stupor, coma, and death if underlying causes are not treated. 
Mortality rates among those hospitalized with delirium are as high as 40%.  Deliriums 
characterized by vivid hallucinations, delusion, language disturbance, and agitation must be 
distinguished from psychotic disorders (American Psychiatric Association, 2013, p.600). 
Estimations of prevalence of visual hallucinations among delirious patients are as high as 75% 
(Cummings & Miller, 1987). The presence of visual hallucinations should prompt a provider to 
strongly consider organic origins or delirious states. Fear and anxiety are often present with 
atypical affect. Orientation and short-term memory are frequently impaired and illogical thought 
or loosening of associations may appear. Delirious patients may frequently identify someone 
unfamiliar, such as a new doctor, as being someone familiar. Deliria tend to fluctuate and often 
worsen at night, which is called “sundowning” (Shea, 1998, p. 326). Delirium may be difficult to 
distinguish from other neurocognitive disorders, particularly in individuals with unrecognized 
neurocognitive disorders. Furthermore, a delirium may be superimposed on another 
neurocognitive disorder.  However, delirium is often recognized by acuteness of onset, 
fluctuation of course, and often disturbance in the sleep/wake cycle (American Psychiatric 
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Association, 2013). Common causes of delirium are infection, metabolic disorders, neurologic 
disorders, post-operative sequelae, and substance/medication intoxication or withdrawal.  
Infections can be intracranial such as encephalitis of meningitis, or systemic, such as urinary 
tract infection, pneumonia, septicemia, typhoid and malaria. Common metabolic disorders 
include electrolyte imbalance, hyperglycemia, hypoglycemia, hypoxia, hypercarbia, anemia, 
abnormal levels of calcium or magnesium, vitamin-B deficiency, liver or kidney disease, and 
endocrine disorders such as hyperthyroidism, hypothyroidism, and adrenal disorders. Neurologic 
disorders that may cause delirium include trauma, seizures, stroke, hypertensive crisis, 
subarachnoid hemorrhage, and vasculitits (Shea, 1998). Even in patients with known psychotic 
disorder, if their psychotic presentation generally presents in similar manner and then presents in 
an atypical manner, additional etiology should be considered, because delirium warrants 
aggressive medical evaluation and this may be overlooked in patients with chronic psychiatric 
conditions. The provider should especially attend to significant problems with attention and 
fluctuating levels of consciousness (Shea, 1998). 
Considerations at this juncture include: 
1. Does the patient meet criterion for delirium with disturbance in attention and 
awareness? 
2. Is immediate medical referral and intervention necessary for the safety of the 
patient? 
3. Has this type of delirium occurred before and in what circumstances? 
4. What is the course of the appearance of psychiatric dysfunction? 
5. Are there co-morbid conditions?  
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6. Is this the appropriate time to diagnose psychiatric dysfunction or should the 
course of the delirium be assessed?  
7. Review medical/psychiatric records if possible to help rule out probable medical 
causes as, well as psychiatric causes. 
8. Assess patient’s performance with a mini-mental status exam or other quick to 
administer and score repeatable measure, so that scores can be compared to each 
other over a short time period.  
9. Even if the patient has a psychiatric history, if the symptoms are different and 
consistent with delirium, rule-out delirium. 
 
Mild and Major Neurocognitive Disorders 
 
According to the DSM-5, “The Neurocognitive Disorders (NCDs) are unique among 
DSM-5 categories in that there are syndromes for which the underlying pathology, and 
frequently the etiology as well, can potentially be determined” (p. 591).  This statement brings 
forth several questions.  First if the etiologies are able to be determined, why not label them as 
such using the appropriate medical code that is already in place versus using two to three codes 
with additional specifiers? The question is also raised as to the utility of such general diagnoses 
as Mild NCD.  The diagnosis of Mild NCD seems highly sensitive, not specific, and without a 
reliable gold standard. All that is required to meet diagnostic criteria is (a) evidence of a modest 
decline from a previous level of performance in one cognitive domain (complex attention, 
executive function, learning and memory, language, perceptual–motor, or social cognition) based 
on concern from the individual, a knowledgeable informant, or a clinician, and (b) that the mild 
decline in cognitive function be preferably documented by neuropsychological testing, or in its 
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absence, by another quantified clinical assessment (American Psychiatric Association, 2013).  
Questions of what constitutes modest decline and other quantified clinical instrument are raised, 
given that the base rates for “normals” to have declines of one standard deviation is 
psychometrically normal.  The clinician is then to specify if possible whether the NCD is due to: 
Alzheimer’s disease, frontotemporal lobar degeneration, Lewy body disease, vascular disease, 
traumatic brain injury (TBI), substance/medication use, HIV infection, Prion disease, 
Parkinson’s disease, Huntington’s disease, another medical condition, multiple etiologies or 
unspecified etiology.  Finally the diagnoses of Major and Mild NCD contains rule outs that the 
cognitive deficits are not better explained by another mental disorder. What if there is a co-
morbid mood disorder that occurs? What if there are symptoms of mood disorder within the 
medical diagnosis? What if a patient with a mood disorder does have impairment in cognitive 
domains? Does that not merit charting as a neurocognitive disorder, especially given the general 
nature of the NCD diagnosis and the lack of appropriate cognitive functioning specifiers of the 
mental disorders?  Finally the DSM-5 hallucination decision tree does not consider the 
possibility of visual hallucinations due to a medical condition without neurocognitive disorder.  
The DSM-5 even recognizes that “the differential diagnosis between normal cognition and mild 
NCD, as between mild and major NCD is challenging because the boundaries are inherently 
arbitrary” (p.610). Major NCD is comparable to dementia of the DSM-IV and prevalence rate at 
65 years of age is estimated at 1-2% and as high as 30% by age 85 (p.608). The DSM-5 states 
that estimates for Mild NCD are comparable with the previous prevalence estimates of mild 
cognitive disorder in the DSM-IV of “2-10% at age 65 and 5-25% by age 85” (p. 608). However, 
since Mild NCD is so close to normal functioning as to be difficult to differentiate, prevalence 
rates could be quite high.  Given the change in diagnostic criteria from dementia there are no 
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prevalence rates available for the general Mild NCD. Which again raises the question of the 
utility of the diagnosis of Mild NCD.  
Considerations at this juncture include: 
1. Is there a medical condition that better explains the psychiatric symptom of 
visual hallucination? 
2. Has the patient had recent medical care?  
3. Is a referral recommended? 
4. Is neuropsychological testing necessary or is medical diagnostic testing 
necessary? 
5. Does the patient’s medical or psychiatric diagnostic history identify a potential 
etiology? 
6. Is this psychiatric presentation consistent with previous diagnosis and 
previous psychiatric symptoms if any? 
7. Are there other neurologic symptoms? 
8. Are there any psychiatric symptoms? 
9. Are psychiatric symptoms consistent with a psychiatric diagnosis, or 
inconsistent, potentially indicating alternate diagnosis? 
10. As with other junctures of the decision tree consider age and the prevalence 
rate for the most likely conditions given the patient’s presentation and age. 
 
Visual Hallucinations and Medical Disorders 
An awareness of medical diagnoses that mimic psychiatric disorders and may present 
with visual hallucinations is important to keep in mind, in addition to the physiological and 
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medical etiologies of delirium. This list is in no way complete, but rather a short list of the 
medical diagnoses that most often present with visual hallucinations.  The prevalence rates of 
these disorders will be presented.  Disorders to be discussed include Lewy body disease, 
Parkinson’s disease, Alzheimer’s disease, vascular dementia, narcolepsy, Huntington’s disease, 
Creutzfeldt-Jakob disease, migraine, epilepsy, seizure, stroke, and traumatic brain injury, as well 
as vision loss related, retinal pathology, and Charles-Bonnet syndrome (Cummings & Miller, 
1987; Liu, Volpe, & Galetta, 2010; Teeple et al., 2009). The diagnoses below, which often 
present with visual hallucinations, are not to be confused with the diagnosis of psychotic disorder 
due to a general medical condition. The diagnosis of psychotic disorder due to a medical disorder 
“is generally not diagnosed” if reality testing regarding the hallucinations is maintained or the 
patient can appreciate that the hallucinations are part of a medical condition. The prevalence rate 
of psychotic disorder due to medical condition is estimated at 0.22% (Perala et al., 2007). 
Neurological disorders 
Parkinson’s Disease 
Prevalence rates for Parkinson’s disease are 0.3-0.4% for the general population, up to 4.5 % for 
the population of those over age 85 (Blin et al., 2015). Prevalence rates for visual hallucinations 
among those diagnosed with Parkinson’s disease are between 6-40% depending on those studied. 
Lower rates are indicated in the general population and higher rates in medical and assisted 
living settings, as well as at later stages of the disease. Prevalence of mild neurocognitive 
disorder (Mild NCD) is 27% among those diagnosed with Parkinson’s disease. Visual 
hallucinations related to Parkinson’s disease may be due to the disease process, medication 
effects, or sleep disturbance (Liu et al., 2010).  
 Lewy Body Disease  
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In the general elderly population prevalence rate estimates for neurocognitive disorder 
with Lewy bodies range from 0.1%-5.0%. This rate is higher in men than in women by a ratio of 
1.5:1.  Lewy Body disease accounts for 1.7-35% of all dementia cases. Lesions known as Lewy 
bodies are present in 20%-35% of autopsy confirmed dementias. Core features of the disease 
include two out of three of the following features: recurrent well formed visual hallucinations, 
fluctuating cognition with changes in attention and alertness, spontaneous features of 
parkinsonism with the onset of cognitive decline (American Psychiatric Association, 2013, p. 
619). It is estimated that over 77% of patients with Lewy Body dementia have visual 
hallucinations (Del Ser et al., 2000, p. 1034). Hallucinations may become disabling and lead to 
nursing home placement (Liu et al., 2010). Accurate diagnosis is essential because up to 50% of 
those with NCDLB have neuroleptic drug sensitivity.  Other symptoms of Lewy Body disease 
include orthostatic hypotension, autonomic dysfunction, transient loss of consciousness, urinary 
incontinence, syncope, repeat falls, auditory and non-visual hallucinations, delusions, apathy, 
REM sleep disturbance, and depression (American Psychiatric Association, 2013; Del Ser et al., 
2000). The onset of Lewy Body dementia is insidious in the sixth to ninth decades of life. Most 
cases occur in the seventh decade of life and the course of the disease progression is usually 
between five to seven years (American Psychiatric Association, 2013). Lewy Body dementia is 
distinguished from Parkinson’s dementia by disease course and onset. In Lewy Body dementia 
the onset of cognitive decline precedes the motor symptoms of Parkinson’s disease by at least 
one year.  It can also be difficult to differentiate Lewy Body dementia  from  Alzheimer’s disease 
as these diseases are frequently is co-morbid, especially in the oldest age groups (American 
Psychiatric Association, 2013) 
Alzheimer’s Disease 
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 Prevalence of visual hallucinations among patients with Alzheimer’s disease is between 
3-33%. Visual hallucinations account for 85% of the hallucinations associated with this disorder. 
According the to 2014 Alzheimer’s Association report, it is estimated that one in nine people 
over the age of 65 has Alzheimer’s disease. Of those affected, two-thirds are women 
(Alzhiemer's Association, 2014). In the context of Alzheimer’s disease, visual hallucinations are 
generally associated with increased cognitive decline and poor prognosis.  Delusions, paranoia, 
and auditory hallucinations may also be present (American Psychiatric Association, 2013). 
 Treatment options for Alzheimer’s disease are limited.  Neuroleptic medications may be 
used for Alzheimer’s patients with visual hallucinations, but anticholinergic medications may be 
contraindicated should be monitored (Liu et al., 2010).  
Stroke  
 The Stroke Association reports that an estimated one percent of those diagnosed with 
stroke may experience psychotic features of hallucinations or delusions. Visual hallucinations 
following a stroke generally start within a few days of the stroke. The hallucinations may subside 
in a few weeks, but they may also be present for years. Peduncular visual hallucinations are 
generally related to mid-brain injury and may be complex, vivid and lifelike. Stroke related 
visual hallucinations are often co-occur with sleep disturbance, ataxia, and cognitive disturbance  
(Liu et al, 2010).   
Migraine 
Visual hallucinations with migraine are usually simple and consist of aura, spectra, 
squiggles, dots, prisms, halos, or flashing lights usually followed by a headache. Auras are the 
most common and occur in approximately one-third of migraine patients. These typically last 
from a few minutes to an hour, but may last for up to a week. Vaso-constriction induced cortical 
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ischemia were originally thought to cause auras, but recent research has suggested neuronal 
dysfunction from cortical depression. Complex visual hallucinations of people and animals, and 
visual distortions such as size distortions of one’s own body or surroundings do occur with 
migraines, albeit rarely (Liu et al., 2010). 
Epilepsy/Seizures 
Visual hallucinations are not uncommon in patients with epilepsy. Studies indicate that 
among patients with occipital lobe epilepsy 60% have simple hallucinations (Liu et al., 2010). 
Visual field defects are associated with occipital lobe epilepsy, but patients may be unaware of 
their deficit. Complex hallucinations are more frequently associated with temporal lobe epilepsy 
but are reported by 10% of patients with occipital lobe epilepsy. Between 16-18% of patients 
with temporal lobe epilepsy have visual hallucinations. However, hallucinations in temporal lobe 
epilepsy are more likely to involve other senses than those of the occipital lobe. Visual 
hallucinations associated with parietal lobe epilepsy are uncommon (Liu et al., 2010).    
Narcolepsy 
The prevalence of narcolepsy in the general population is 0.01-0.18% (Talih, 2011). 
Narcolepsy usually affects those between ages 5-55, but it is most prevalent among those in their 
20s (Liu et al, 2010). Narcolepsy may be overlooked and misdiagnosed for years before the 
correct diagnosis is made (Cummings & Miller, 1987) and the appropriate treatment given 
(Duwe & Turetsky, 2002; Talih, 2011). Patients with narcolepsy may view themselves as having 
a psychiatric disorder prior to correct diagnosis. Patients have reported not realizing that their 
hallucinations were related to a sleep disorder since they could occur during the day where 
patients were unaware that they were momentarily going in and out of sleep states (Sacks, 2013; 
Cummings & Miller, 1987). 
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Visual hallucinations occurring in narcolepsy are generally complex and often associated 
with auditory and tactile hallucinations. The duration of these visual hallucinations is variable, 
ranging from a few seconds to minutes. They often occur regularly: for some on a daily basis. 
Insight is usually, but not always intact. When insight is compromised, hallucinations may be 
misattributed to some other cause in order to make sense of them (Sacks, 2013). Patients may 
appear to have unusual, magical thinking, or delusional thinking as well (Ohayon, 2000; Sacks, 
2013; Szucs, Jansky, Hollo, & Migleczi, 2003). Symptoms associated with narcolepsy include 
hypnogogic hallucinations, excessive daytime cataplexy, sleepiness, or sleep paralysis (Szucs et 
al., 2003; Talih, 2011).  
There are tests available to identify narcolepsy, including measurement of hypocretin 
levels in cerebrospinal fluid, huford leukocyte antigen (HLA) typing, and mean sleep latency 
testing (MSLT). Treatment for narcolepsy typically includes wake promoting agents and central 
nervous system stimulants. Selective serotonin reuptake inhibitors and serotonin norepinephrine 
reuptake inhibitors may be used when cataplexy is a part of the clinical picture. However, 
antipsychotic drugs are often contraindicated in the treatment of narcolepsy (Talih, 2011, p.31).   
Vision Impairment and Visual Hallucinations 
Complex visual hallucinations with insight occur among those with acquired visual 
impairment. These hallucinations are not related to chronological age and the individuals may be 
cognitively intact (Menon, 2005) and psychologically normal (Teunisse, Zitman, Cruysberg, 
Hoefnagles, & Verbeek, 1996).  Many of the patients with visual impairment associated with 
hallucinations have reported that they would not have told their physicians about having 
hallucinations, if not asked directly, for fear of being thought to have a psychiatric illness or 
dementia (Holroyd, Rabins, Finkelstein, Nicholson, Chase, & Wisniewski, 1992; Menon, 2005). 
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Training physicians to educate patients and ask in a manner that does not suggest psychiatric 
illness may be helpful (Holroyd et al., 1992). Patients found reassurance in learning that their 
visual hallucinations did not represent additional pathology (Menon, 2005).  
Macular Degeneration 
Estimated prevalence rate for visual hallucinations amongst those with age-related 
macular degeneration is 13%. Significant variables include bilateral vision loss, particularly with 
visual acuity of 20/60 or worse, living alone, history of stroke, and lower scores on cognitive 
testing (Holroyd et al., 1992). 
Retinal Disease  
Prevalence rate for visual hallucinations in patients with retinal disease is 15%.  These 
hallucinations last from a few seconds to minutes (Scott, Schein, Feuer, & Folstien, 2001).   
Charles Bonnet Syndrome 
 Charles Bonnet syndrome is characterized by complex release hallucinations in 
psychologically normal individuals. The release hallucination is a spontaneous visual response, 
which may be due to lack of inhibitory input such as seen with hallucinations by prisoners of war 
who experienced sensory deprivation. Charles Bonnet syndrome has been used as a catchall term 
for diagnosing those with release visual hallucinations who were considered psychologically 
normal. Most patients with diagnosed Charles Bonnet syndrome have incurred vision loss. Those 
with Charles Bonnet syndrome typically have macular degeneration, cataracts, diabetic 
retinopathy, glaucoma, or corneal disease (Liu et al., 2010). The hallucinations experienced may 
last from a few seconds to hours. Estimated prevalence rates among those who have visited an 
ophthalmologist is less than 0.5% (Shiraishi, Terao, Ibi, Nakamura, & Tawara, 2003).  The 
estimated prevalence rate among those with low vision is between 12.8%-17.5% for complex 
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visual hallucinations and 50% for simple visual hallucinations (Reichert, Series, & Storkey, 
2013).  
Conversion Disorder 
At this juncture the DSM-5 diagnostic decision tree for hallucinations asks the clinician 
to consider conversion disorder. However, there are no prevalence rates available for transient 
conversion disorder. The incidence for persistent conversion symptoms is estimated to be 2-
5/100,000 or 0.00002% to 0.00005%. Dissociative symptoms are more common in the disorder. 
Although visual hallucinations may occur in conversion disorder, they are not listed as a primary 
symptom.  Visual symptoms such as tunnel vision are listed as possible diagnostic features. 
Comorbid conditions common with conversion disorder include depressive disorders, anxiety 
disorders, somatic symptom disorder, personality disorders, neurologic disorders and other 
medical conditions. A history of trauma is also common with conversion disorder. Conversion 
disorder is more common in women. Ruling out neurological disease, somatic symptom disorder, 
factitious disorder, dissociative disorder, body dysmorphic disorder, and panic disorder is part of 
differentially diagnosing conversion disorder.  Given the low incidence rate, other potential 
diagnoses should be considered first.  
 
Culturally Sanctioned Visual Hallucinations 
The next juncture asks the clinician to determine if a hallucination is culturally sanctioned. For 
example in the United States visual hallucinations as a part of a grief response are not considered 
pathological. Grief hallucinations occur across cultures. Visual hallucinations of “seeing” the 
deceased are usually brief. Prevalence rates for hallucinations related to grief response are 
estimated from 10% to 41%; Rates are higher among those who are widows or widowers after 
age 40.  These rates are between 23% to 41% for college students. Prevalence rates of visual 
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hallucinations are higher in those with pathological conditions such as PTSD, Charles Bonnet 
syndrome, or reactive psychosis (Collerton, Mosimann, & Perry, 2015). Clinicians should weigh 
the degree to which a patient is having these hallucinations. Is it a brief vision of the loved one as 
a potential part of the psychological process of mourning, or is the person having long periods of 
imagining their loved one there with them, unaware that they are not actually with them? Just 
because the subject matter of the hallucination may be culturally sanctioned does not mean the 
etiology behind the hallucination is not pathological.  
Psychotic Disorders 
 
Visual hallucinations occur in psychiatric disorder, including schizophrenia spectrum 
disorders, bi-polar disorder with psychotic symptoms, depression with psychotic symptoms, and 
brief psychotic disorder. In psychiatric disorders, auditory hallucinations are more common than 
visual hallucinations, and visual hallucinations are generally, but not always accompanied by 
auditory or tactile hallucinations, although not necessarily simultaneously. The duration of 
hallucinations in psychiatric disorder is variable. The lifetime prevalence for all psychotic 
disorders is between estimated between 3- 3.5% (Perala et al., 2007).  
Affective Disorders with Psychotic Features 
 The next two junctures of the decision tree ask the clinician to determine whether the 
symptoms occur in the context of a manic or depressed mood. Estimated prevalence rates for 
Bipolar I Disorder with psychotic features (which may or may not include visual hallucinations) 
is 0.24%. The estimated prevalence rate for Major Depressive Disorder with psychotic features is 
0.35% (Perala et al., 2007).  The estimated prevalence rate for visual hallucinations among 
patients diagnosed with affective disorders with psychotic features is 15% (Waters et al., 2014). 
VISUAL HALLUCINATION DIFFERENTIAL DIAGNOSIS CHART  36 
 The junctures for affective psychotic disorders are listed in the decision tree before 
schizophrenia spectrum disorders. However, it is important to remember that prevalence rates 
indicate that visual hallucinations with these disorders are statistically less common than visual 
hallucinations with schizophrenia spectrum disorders.    
 Schizophrenia Spectrum Disorders  
The next junctures asks the clinician to consider nonaffective/schizophrenia spectrum 
psychiatric disorders by assessing length of time psychotic symptoms have been present, and by 
assessing for delusions, disorganized speech, grossly disorganized or catatonic behavior, and 
negative symptoms of schizophrenia spectrum disorders.  
Schizophrenia. Schizophrenia has a lifetime prevalence rate in the general population of 
0.3% to 0.87%. Research has indicated some variance in rates by ethnicity and race (American 
Psychiatric Association, 2013; Perala et al., 2007). Between 16% to 72% of individuals 
diagnosed with schizophrenia have visual hallucinations: the higher percentages are from studies 
of individuals on inpatient units (Mueser, Bellack, & Brady, 1990) and often occur with auditory 
hallucinations. Comparatively, 74% of people with a diagnosis of schizophrenia experience 
auditory hallucinations (Sartorius, Shapiro, & Jablensky, 1974). International studies indicate 
that culture impacts hallucination prevalence rates: auditory hallucinations are universally more 
common among those diagnosed with schizophrenia across cultures with prevalence rates from 
66% to 90.8%. Visual hallucinations were far less prevalent with rates between 3.9% to 53.9%. 
The highest prevalence rates for both types of hallucinations were found in Nigeria and Ghana 
(Bauer et al., 2011, p. 322).  
Onset is typically in the late 20s for females and early to mid 20s for males.  “Late onset 
cases can still meet diagnostic criteria for schizophrenia, but it is not yet clear whether this is the 
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same condition as schizophrenia diagnosed prior to mid-life” (American Psychiatric Association, 
2013, p. 103). Males tend to have more negative symptoms than females. Impaired cognition is 
common even when other symptoms are not active. Neuropsychological research has indicated 
abnormalities associated with schizophrenia, but none diagnostic. No laboratory or psychometric 
tests conclusively identify schizophrenia (American Psychiatric Association, 2013). Medical 
comorbidity of patients with a diagnosis of schizophrenia should be considered. Studies have 
indicated that some patients' mental symptoms are caused or exacerbated by undiagnosed 
medical conditions (Jeste, Gladsjo, Lindamer, & Lacro, 1996).  
Schizoaffective. Schizoaffective disorder has a lifetime prevalence rate of 0.3%. As with 
schizophrenia, hallucinations are more commonly auditory, but may be visual.  The general 
course is two months of auditory hallucinations or delusions followed by a depressive period. It 
is important to remember that part of the diagnosis is a major mood episode of either bipolar or 
depressive type. Differentiating schizoaffective disorder from mood disorder with psychotic 
features can be challenging. The distinguishing criteria are major mood episode present the 
majority of the duration of active and residual symptoms, as well as two or more weeks of 
delusions or hallucinations when no major mood episode is present. Onset is generally in early 
adulthood but can occur anywhere from adolescence to late life. Females are diagnosed with 
schizoaffective disorder more frequently than males and have more depressive symptoms 
(American Psychiatric Association, 2013).  
Schizophreniform. Incidence of schizophreniform disorder is low. In the United States it 
is “possibly five-fold less than schizophrenia” with an estimated prevalence rate of 0.07% 
(American Psychiatric Association, 2013, p. 98). Approximately one-third of those diagnosed 
with schizophreniform disorder will recover in 6 months. “The majority of the remaining two-
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thirds will eventually receive a diagnosis of schizophrenia or schizoaffective disorder” 
(American Psychiatric Association, 2013, p. 98). Information on prevalence rates of visual 
hallucinations related to schizophreniform disorder is lacking.  
Other Schizophrenia Spectrum and Other Psychotic Disorders 
At this juncture the clinician is asked to consider other schizophrenia spectrum and 
psychotic disorders. However, no other criteria are suggested.  In this diagnosis the clinician is to 
document and specify the presenting psychotic symptom. The clinician is to also document why 
full criteria are not met. Unspecified schizophrenia spectrum and other psychotic disorders are 
vague as to diagnostic criteria and the DSM-5 states that this diagnosis is made when a clinician 
chooses “not to specify the reasons that schizophrenia spectrum or other psychotic disorder 
criteria are not met.” Prevalence rates for these diagnoses are unavailable. These diagnoses lack 
diagnostic clarity and their utility is limited, outside of documentation.   
Brief Psychotic Disorder 
 At this juncture the clinician is asked to consider brief psychotic disorder if symptoms are 
present more than one day but less than one month. Brief psychotic disorder accounts for 9% of 
cases of first-onset psychosis. This disorder may occur at any age, but may be more common in 
the 30s and in patients with personality disorders or personality disorder traits.   
Important considerations regarding possible psychiatric related visual hallucinations 
include: 
1. Age of the patient. 
2. Does age of onset of symptoms suggest schizophrenia? 
3. Is there a history of auditory hallucinations?  
4. Are there negative symptoms? 
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5. Are there delusions? 
6. Is there disorganized speech? 
7. Is there disorganized or catatonic behavior?  
8. Does the patient have insight regarding the hallucinations? 
9. If the patient does not have insight what is the response to having the event 
labeled a hallucination? 
10. Is the onset of symptoms: acute or insidious? 
11. What is the duration of the symptoms? 
12. Do the symptoms occur within or outside of mood disorder? 
13. Are the hallucinations hypnopompic or hypnogogic? 
14. What occurred before onset of symptoms, any changes? 
15. If the patient has a history of affective or nonaffective psychiatric disorder, are the 
symptoms different this presentation? 
16. Substance/medication use and discontinuation history 
17. Medical history of the patient 
18. Psychiatric history of the patient  
19. Patient’s family medical, neurologic, and psychiatric history 
20. History of head injury 
21. Trauma history  
22. Educational history 
23. Social and work history 
24.  Is the patient an accurate historian? 
25. Is psychological or neuropsychological testing suggested? 
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Additional Psychiatric Considerations 
 Trauma related flashbacks should be distinguished from visual hallucinations. PTSD has 
high comorbidity with other psychiatric disorders. If visual hallucinations are present other 
medical, psychotic, and personality disorders should be considered (American Psychiatric 
Association, 2013).   
Hallucinations Not Covered Above 
At this juncture the DSM-5 decision tree asks the clinician to consider diagnoses not 
covered earlier in the diagnostic decision tree, without any guidance as to possible etiologies 
except to reconsider a schizophrenia disorder or psychotic disorder if there is clinically 
significant impairment or distress. Even though the visual hallucinations may be one symptom of 
psychosis they “are not pathognomonic of a primary psychiatric illness” (Teeple et al., 2009, p. 
26), even if clinically significant and causing distress. Note that there are no guidelines as to 
what defines “clinically significant” or “distress.” The logic at this juncture is somewhat circular 
and is prone to attribution error given the lack of diagnostic sensitivity or specificity, and does 
not acknowledge that the etiology of the majority of psychiatric conditions is unknown 
(American Psychiatric Association, 2013). Also the utility of diagnoses at this juncture is limited.  
The decision tree does not allow for the consideration of referral to another medical specialist 
and does not allow for lack of knowledge of the etiology of the visual hallucination.  
The alternate diagnosis or lack of diagnosis at this point is “nonpathological,” which 
according to the decision tree indicates that the visual hallucination does not cause significant 
clinical impairment or distress. This may or may not be true. For example, a patient may not 
have distress regarding visual hallucinations, but that patient may have a medical or psychiatric 
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condition that has yet to be identified. Again this juncture does not allow for the consideration of 
many of the possible conditions described in this paper, or the unknown.  
Considerations at the final junctures include: 
1. Review data for what could have been missed. Could the hallucination be related 
to unknown or unrecognized medical disorders, psychiatric disorders, or 
substance/medication use or withdrawal? 
2. Are there accompanying neurologic symptoms? 
3. Is a medical referral in order? 
4. Is referral to another clinician in order? 
5. Is the hallucination related to sleep disturbance? 
6. What does the visual hallucination mean to the patient? 
7. What is the function of the hallucination? 
8. What is the context of the hallucination? 
9. Inform and educate the patient regarding possible medical, substance/medication, 
metabolic, ophthalmologic, psychiatric, and neurologic etiologies. 
10. Inform the patient that you do not know the cause. 
11. Consider possible secondary gain. 
Conclusion 
 
 Differential diagnosis related to the symptom of visual hallucinations can be challenging 
given the wide variety of underlying etiologies, potential health risks, and consequences 
associated with both the underlying etiology, as well as potential damage of misdiagnosis and 
incorrect treatment. Although visual hallucinations are generally perceived to be a symptom of 
psychiatric disorder, they are more commonly associated with neurological or medical disorders, 
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sensory impairment, or substance intoxication or withdrawal. In this paper I summarized the 
most prevalent causes of visual hallucinations, reviewed the DSM-5 hallucination decision tree, 
and provided an annotated visual hallucination differential diagnosis decision tree. It is in no way 
inclusive of all the causes of visual hallucinations, underlying mechanisms, or treatment options. 
The causes of visual hallucinations are too numerous, and the treatment options too varied to 
cover in the scope of this paper. However, it is my hope that this paper may serve as a reminder 
of those causes, which are both psychiatric and non-psychiatric so that trainees like myself may 
be more aware and open to diagnoses outside of our training to help limit attribution error related 
to psychiatric diagnosis. Also I hope it serves as a reminder to re-examine diagnosis when the 
course of the symptoms is not as expected and response to treatment is not as expected.  
 Information related to visual hallucination prevalence is limited and unavailable for many 
disorders. This may be in part due to the fact the many patients do not report visual 
hallucinations out of fear of being seen as having psychiatric disorder. Also, data may be limited 
by clinicians assuming that visual hallucinations are psychiatric or organic in nature depending 
on the specialty and diagnostic frame of the clinician. The data that is available is from multiple 
studies over many decades. During that time diagnostic criteria have been altered and additional 
diagnoses have been discovered. For example, it is likely that some individuals studied as having 
schizophrenia in older studies may now be recognized as having had a stroke or dementia with 
Lewy bodies. It is important to remember that diagnoses change and that a diagnosis often is 
used in a top to bottom approach, which may lead to attribution error.  Keeping in mind 
prevalence rates is one way to help check attribution error. However, it is likely that studies of 
prevalence rates may also be influenced by attribution error and diagnostic error.  
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 Figure 1.0. DSM-5 Handbook of Differential Diagnosis Decision Tree for Hallucinations 
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